Gilead Sciences A.I CyberSecurity Scoring
20/05/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Gilead Sciences in 2026.
No incidents recorded for Gilead Sciences in 2026.
No incidents recorded for Gilead Sciences in 2026.
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
Latest updates, reports, and threat intel affecting the global network.
Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies. Our valuation framework helps you...
Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than...
Boulder Ventures, founded in the 1980s by Baltimore lawyers Larry Macks and Josh Fidler, has joined a $42 million Series A for RapidFort,...
Here's why analysts believe Gilead Sciences (NASDAQ: GILD) could see about 3% upside by 2027, driven by steady HIV growth, new drug launches...
These are the stocks posting the largest moves in midday trading.
Gilead invests in world-class science and is pursuing innovation across the therapeutic areas of virology, oncology and inflammation.
Harbin Clinic has been affected by a cyberattack on the debt collection agency Nationwide Recovery Service, Gardner Health Services has fallen victim to a...
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Co. (DIS), Gilead Sciences, Inc. (GILD) and Eaton Corp. plc...
With the acceleration of digital transformation, the cyber talent gap has widened to a chasm. According to the most recent Cybersecurity Workforce Study by...
The GOOSE subscriber component improperly validates the UTC timestamp field in unauthenticated IEC 61850 GOOSE (EtherType 0x88B8) Layer-2 multicast messages. A specially crafted GOOSE frame containing an undersized timestamp field can trigger a heap out-of-bounds read during message processing, causing the process to crash and resulting in a denial-of-service condition.
OpenClaw Dashboard contains a stored cross-site scripting vulnerability that allows unauthenticated remote attackers to execute arbitrary JavaScript in the administrator's browser session by injecting HTML markup into agent transcript messages processed through the sessions API. Attackers can craft a message containing inline event handler payloads such as an img tag with an onerror attribute within the 60-character rendering budget, which is stored in the session transcript and interpolated unsanitized into innerHTML on the default landing page, allowing theft of session tokens and unauthorized calls to authenticated administrative endpoints including agent instruction file modification.
MeshCentral 1.1.21 contains a cross-site WebSocket hijacking protection bypass vulnerability that allows unauthenticated remote attackers to hijack authenticated administrator sessions by exploiting an unconditional early return in the CheckWebServerOriginName() function within webserver.js when self-signed certificates are in use. Attackers can open cross-origin WebSocket connections to any of the twelve WebSocket endpoints, send crafted action commands to exfiltrate the server sessionKey used to sign session cookies, forge session tokens as arbitrary users, and gain full remote control of all managed devices governed by the MeshCentral instance.
The GOOSE parser contains an off-by-one boundary-handling flaw that can be triggered by a single unauthenticated Layer-2 multicast frame on the process bus. When specific GOOSE message fields are processed, the parser advances its internal buffer position incorrectly, resulting in a heap out-of-bounds read. On affected platforms, this condition reliably terminates the subscriber process and causes a denial-of-service.
The GOOSE payload parser contains a boundary handling flaw that can be triggered by a single unauthenticated Layer 2 multicast frame on the process bus. When processing specific payload fields, an attacker controlled inner element length may exceed its enclosing length, causing the parser to over read by one byte. This out-of-bounds read reliably terminates the subscriber process, resulting in a denial-of-service condition.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.